CymaBay Therapeutics Revenue and Competitors

Location

#2396

Growjo Ranking

Pharma

Industry

Estimated Revenue & Valuation

  • CymaBay Therapeutics's estimated annual revenue is currently $6.8M per year.(i)
  • CymaBay Therapeutics received $Undisclosed in venture funding in January 2018.
  • CymaBay Therapeutics's estimated revenue per employee is $56,016
  • CymaBay Therapeutics's total funding is $276M.
  • CymaBay Therapeutics's current valuation is $266.7M. (January 2022)

Employee Data

  • CymaBay Therapeutics has 122 Employees.(i)
  • CymaBay Therapeutics grew their employee count by 61% last year.

CymaBay Therapeutics's People

NameTitleEmail/Phone
1
President and CEOReveal Email/Phone
2
VP, Manufacturing and Supply Chain OperationsReveal Email/Phone
3
VP, Clinical DevelopmentReveal Email/Phone
4
VP Clinical OperationsReveal Email/Phone
5
SVP Business DevelopmentReveal Email/Phone
6
VP Market AccessReveal Email/Phone
7
VP FinanceReveal Email/Phone
8
SVP, Human ResourcesReveal Email/Phone
9
VP Commercial OperationsReveal Email/Phone
10
VP Nonclinical Development and Project ManagementReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$84.8M42224%N/AN/A
#2
$0.4M20%N/AN/A
#3
$32M1593%N/AN/A
#4
$35M1213%$62.5MN/A
#5
$30.2M15018%N/AN/A
#6
$135.3M6730%N/AN/A
#7
$110.3M549N/AN/AN/A
#8
$60.1M299-4%N/AN/A
#9
$554.8M17252%N/AN/A
#10
$10.5M524%N/AN/A
Add Company

What Is CymaBay Therapeutics?

CymaBay Therapeutics, Inc. (CBAY) is a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet medical need. Seladelpar is a potent, selective, orally active PPAR agonist, currently in development for the treatment of patients with primary biliary cholangitis (PBC), an autoimmune liver disease, and with non-alcoholic steatohepatitis (NASH). For additional information about CymaBay visit www.cymabay.com.

keywords:Biotechnology,Cleantech,Healthcare,Pharmaceuticals,Wind Power

$276M

Total Funding

122

Number of Employees

$6.8M

Revenue (est)

61%

Employee Growth %

$266.7M

Valuation

N/A

Accelerator

CymaBay Therapeutics News

2022-04-17 - Zacks: Brokerages Anticipate CymaBay Therapeutics, Inc ...

Equities research analysts predict that CymaBay Therapeutics, Inc. (NASDAQ:CBAY – Get Rating) will announce earnings per share (EPS) of...

2022-04-17 - Institutional owners may take dramatic actions as CymaBay Therapeutics, Inc.'s (NASDAQ:CBAY) recent 13% drop adds to one-year losses

Hence, if weakness in CymaBay Therapeutics' share price continues, institutional investors may feel compelled to sell the stock, which might not...

2022-03-30 - CymaBay Therapeutics Announces Publication of Results ...

CymaBay Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on improving the lives of people with liver and other chronic...

2021-08-02 - CymaBay secures $100M to bankroll phase 3 development of resurrected liver drug Clinical Quality Oversight Forum

A little over a year after resurrecting the liver disease drug seladelpar, CymaBay Therapeutics now has $100 million to bankroll a phase 3 study of the drug. RELATED: CymaBay resurrects seladelpar 8 months after NASH flop In November, the Newark, California-based biopharma presented data showi ...

2021-08-02 - CymaBay Therapeutics : Announces $100 Million Non-Dilutive Financing with Abingworth

Risk-sharing agreement with Abingworth will fund seladelpar Phase 3 development program for PBC CymaBay retains full worldwide commercial rights to seladelpar NEWARK, Calif., Aug. 02, 2021 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$7.5M12310%N/A
#2
$17.8M123-5%N/A
#3
$18.1M12523%N/A
#4
$90M1264%$15.9M
#5
$43M13118%N/A

CymaBay Therapeutics Funding

DateAmountRoundLead InvestorsReference
2013-10-21$26.8MUndisclosedArticle
2015-08-18$325.0MUndisclosedArticle
2018-01-31$UndisclosedUndisclosedLeerink Partners LLCArticle